Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Abeona Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.

Get ABEO alerts

About Michael Amoroso

Michael Amoroso is recorded as Board Member at Abeona Therapeutics Inc. (ABEO) since April 6, 2023, CEO at Abeona Therapeutics Inc. (ABEO) since March 19, 2021, COO at Abeona Therapeutics Inc. (ABEO) since November 1, 2020 and Chairman at Abeona Therapeutics Inc. (ABEO). The newest filing on record that lists Michael Amoroso as Chairman at Abeona Therapeutics Inc. (ABEO) is dated April 27, 2026. Abeona Therapeutics Inc. reported in an 8-K filed June 12, 2026 that Michael Amoroso resigned as member of the Board of Directors, effective June 11, 2026. Abeona Therapeutics Inc. reported in an 8-K filed April 11, 2023 that Michael Amoroso was appointed Chairman of the Board, effective April 6, 2023. The proxy statement of Abeona Therapeutics Inc. reports total compensation of $1,499,160 for Michael Amoroso in fiscal 2020, including a base salary of $219,071. Michael Amoroso has spoken on 4 earnings calls across 1 company, most recently for Abeona Therapeutics Inc. on July 28, 2021. Abeona Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Abeona Therapeutics Inc. includes Vishwas Seshadri (CEO and Board Member), Brian J.G. Pereira (Chairman and Board Member), Edward Carr (CFO) and 7 others.

“On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the "Board") of Abeona Therapeutics Inc. (the "Company") effective immediately.”
Abeona Therapeutics Inc. Form 8-K, filed June 12, 2026 · Read the filing
“Also on April 6, 2023, Michael Amoroso, Chairman of the Board, relinquished his seat as a Class 2 director and was immediately appointed as a Class 1 director by the Board to stand for reelection at the 2023 Annual Shareholder Meeting.”
Abeona Therapeutics Inc. Form 8-K, filed April 11, 2023 · Read the filing

Michael Amoroso on recent calls

“We're all excited to be with you today, and I hope this call finds you and your loved ones safe in these still uncertain times.”
CEO, Abeona Therapeutics Inc. Q2 FY2021 Earnings Call ·
“Good morning to our investor community who are excited to spend some time with you this morning, thank you for joining us. As I approach the midpoint of my first 100 days in the job as CEO, I wanted to start by reviewing three key strategic priorities for Abeona and our team.”
CEO, Abeona Therapeutics Inc. Q1 FY2021 Earnings Call ·
“It's a pleasure to be with you today for our Q4 and full year call. We're enthusiastic about Abeona's progress in developing our novel gene and cell therapies for underserved patient populations, and we remain committed to execution; 2021 is a year for delivery.”
CEO, Abeona Therapeutics Inc. Q4 FY2020 Earnings Call ·
“The Abeona team is excited to be with you this morning. We, at Abeona, remain committed to pursuing the development of our portfolio of advanced and early-stage programs toward providing our novel gene and cell therapies to patients who currently have no approved treatment options.”
COO, Abeona Therapeutics Inc. Q3 FY2020 Earnings Call ·

Affiliation history

Company network

Leadership on record at Abeona Therapeutics Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2020 Abeona Therapeutics Inc. (ABEO) $219,071 $1,499,160

Recent activity